Evidence map›Paper›PMID 32850390›Full record

ArticleFrontiers in oncology2020

Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer-Impact on Prognosis.

Linn Nilsson, Emma Sandén, Somayeh Khazaei, Helga Tryggvadottir, Björn Nodin, Karin Jirström, Signe Borgquist, Karolin Isaksson, Helena Jernström

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Linn NilssonDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Emma SandénDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Somayeh KhazaeiDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Helga TryggvadottirDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Björn NodinDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Karin JirströmDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Signe BorgquistDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Karolin IsakssonDepartment of Clinical Sciences in Lund, Surgery, Lund University, Lund, Sweden.
Helena JernströmDepartment of Clinical Sciences in Lund, Oncology, Lund University and Skåne University Hospital, Lund, Sweden.
Lund University · SESkåne University Hospital · SEKristianstad University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerimmunohistochemistrylifestyleprognosissignal transducer and activator of transcription 3 (STAT3)tamoxifen

Identifiers

PMID32850390
PMCPMC7403202
OpenAlexW3045609561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.